U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940960) titled 'JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia' on March 27.
Brief Summary: This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
B Acute Lymphoblastic Leukemia
B-Non Hodgkin Lymphoma
Intervention:
DRUG: JY231 Injection
...